Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: FDA Orthopedic and Rehabilitation Devices Panel

This article was originally published in The Gray Sheet

Executive Summary

FDA Orthopedic and Rehabilitation Devices Panel: Agenda for Jan. 12-13 meeting at FDA's Parklawn Building in Rockville, Maryland has been rearranged with discussion of a reclassification petition for constrained elbows moved up one day to Jan. 12, along with originally scheduled petitions for non-and semi-constrained shoulders. Renew of petitions for patellofemoral knees and uni- and total patellofemorotibial knees has been rescheduled from Jan. 12 to Jan. 13, alongside the originally planned discussion of the classification of calcium sulfate pre-formed pellets (plaster of paris pellets). Contact panel secretary Jodi Nashman at 301/594-2036 for further information...

You may also be interested in...

Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch

As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.

PMDA Eyes More Japan-First Approvals In Access Push

Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts